FDA Asks Antidepressant drug companies to add Cautions on labels Mon, 22 Mar 2004 The FDA has “requested” drug companies to put prominent warnings on the labels of 10 antidepressant drugs, “to include stronger cautions and warnings about the need to monitor patients for the worsening of depression and the…
Testing Psychotropic Drugs in Children April 30, 2002 David Healy, MD University of Wales College of Medicine April 30th 2002. The background against which this paper is prepared is that in 1997 I organized, chaired and wrote up the recommendations from an International Roundtable Meeting for the British Association for…
Antidepressant Makers Withhold Data on Children – Washington Post Thu, 29 Jan 2004 A front page article in The Washington Post addresses the key issue undermining public health and safety. Drug companies conceal unfavorable clinical trial findings: the tests failed to demonstrate that antidepressants are either safe or beneficial for…
Reply to the American College of Neuropharmacology’s Report on SSRI and Suicidal Behavior in Children Jonathan Leo, Ph.D. Introduction The American College of Neuropsychopharmacology (ACNP) recently released an Executive Summary from its Task Force on SSRIs and Suicidal Behavior. The task force concluded that "taking Selective Serotonin Reuptake Inhibitors (SSRIs)…
What Parents Aren’t Being told about their Kids Antidepressants – A Suicide Side-Effect? – SF Chronicle Sat, 10 Jan 2004 An in-depth article in The San Francisco Chronicle reveals how the hidden hazards of SSRIs put adolescents’ lives in danger. For one 16 year old teenager, Paxil posed greater risks…
Randomized Controlled Trials: Evidence Biased Psychiatry By David Healy, MD MRCPsych Introduction A new drug gets introduced to the market. It has been approved after stringent scrutiny by the FDA, which requires ever more convincing evidence that it works and that its safe. The new treatment will always cost more…
Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Fri, 19 Dec 2003 Carl Elliott is a clear eyed academic who teaches bioethics at the University of Minnesota . He is currently a visiting associate professor at School of Social Sciences at the Institute for Advanced Study at Princeton….
ACNP Summary Report Criticized as “Junk Science” Sun, 25 Jan 2004 related links: Reply to ACNP Report – Jonathan Leo, Ph.D. FDA Sham Conflicts of Interest Policy Most of the National press coverage of the controversy swirling around the claims and counter claims about drug suicidal obsessive thinking and behavior…
Dr. Wolpe’s Accusations and Dr. Healy’s Response —–Original Message—– From: Paul Root Wolpe Sent: Tuesday, October 28, 2003 4:30 PM To: VERACARE Subject: Re: Ethics of U Penn surgical “drug implant” experiment Vera, We will have to agree to disagree, so this will be my last email on this. A…
UK issues ban on second SSRI antidepressant for children Sun, 21 Sep 2003 The UK Observer reports (below) that although antidepressant drugs of the SSRI class have not been approved for children, last year doctors (who are unaware of the severe risks associated with SSRIs) wrote 170,000 prescriptions of antidepressants…
Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry– Multi-Discipline Conference_ NYC Mon, 4 Oct 2004 An Op Ed article in The Washington Post by Shannon Brownlee (below) nails the elite procurers of psychotropic drugs who have long denied the ominous signals of drug-induced harm: “You’d think the psychiatric research…
Bioethics Debate: Ethics of U Penn Surgical “Drug Implant” Experiment This debate between AHRP President, Vera Sharav and Bioethicist, Paul Root Volpe, Ph.D., University of Pennsylvania, was prompted by an October 7 infomail. The reasons for AHRP’s opposition to drug implants for psychiatric patients are explained here: https://ahrp.org/ahrpspeaks/drugimplant1103.php —–Original Message—–…
